Market Trends of Global Cancer Monoclonal Antibodies Industry
This section covers the major market trends shaping the Cancer Monoclonal Antibodies Market according to our research experts:
Trastuzumab (Herceptin) is Expected to Hold Significant Market Share in Monoclonal Antibody Therapies
Trastuzumab (Herceptin) is a monoclonal antibody used to treat breast cancer. It is also an approved first-line treatment for HER2+ metastatic cancer of the stomach or gastro-esophageal junction. The country witnessed continued growth, mainly, due to the longer duration of treatment in combination with Perjeta. The high prevalence of cancer globally will drive the studied segment growth. For instance, according to World Health Organization (WHO) update in March 2021, in 2020, there were 2.3 million women diagnosed with breast cancer globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world's most prevalent cancer. Thus, the high prevalence of breast cancer will boost the demand for Herceptin monoclonal antibodies for treating it, thereby boosting the market.
The approval of products in the studied segment is expected to drive market growth. For instance, in January 2021, the antibody-drug conjugate trastuzumab deruxtecan has been granted conditional approval in the European Union for use as a single agent in the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-based regimens. Additionally, in May 2021, the United States Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Thus, owing to the abovementioned factors, the market segment is expected to propel the growth of the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The market is growing at a strong pace in North America. The pharmaceutical and biotechnology firms have gained abundant knowledge and expertise in cancer monoclonal antibodies.
According to the estimates of the 2022 American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also states that 79,000 new cases of kidney cancer will be reported in 2022 from Kidney cancer. The high burden of cancer is expected to boost the demand for ablation devices, thereby driving the market growth.
Additionally, product approvals in the region will further drive market growth. For instance, In July 2021, Merck received United States Food and Drug Administration (FDA) for KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery, based on Phase 3 KEYNOTE-522 trial. In December 2020, MacroGenics, Inc. received United States Food and Drug Administration (FDA) approval for MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Moreover, depending on the high percentage of molecules that are in the pipeline, this scenario may change. Human monoclonal antibody (mAb) is the fastest-growing category in the market. Additionally, with the trend toward developing targeted therapeutics, the focus on fully-humanized cancer monoclonal antibodies is expected to increase, owing to the perceived low level of immunogenicity of these agents. Thus, due to the above-mentioned factors, the studied market is expected to grow during the study period.
